Physician profile
Daniel R Steiner
NPI 1700868502
$18,464.99
in general payments reported to CMS, 2019-2025
38 companies · $1,825 in 2025
The $1,825 reported for 2025 was more than what 92% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $5,383 · 2020: $1,559 · 2021: $2,687 · 2022: $2,699 · 2023: $1,996 · 2024: $2,316 · 2025: $1,825.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,138.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,137.56 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $3,214.33 | 2019-2024 | Xarelto, Spravato |
| Astrazeneca Pharmaceuticals LP | $2,417.13 | 2019-2025 | Breztri, Airsupra, Farxiga |
| Glaxosmithkline, LLC. | $1,842.86 | 2019-2025 | Arexvy, Trelegy Ellipta, Shingrix |
| Novo Nordisk INC | $1,681.39 | 2019-2025 | Wegovy, Ozempic |
| Daiichi Sankyo INC. | $1,236.99 | 2019-2025 | Injectafer |
| Amgen INC. | $931.03 | 2019-2024 | Repatha, Prolia, Evenity |
| Lilly USA, LLC | $819.14 | 2019-2025 | Mounjaro, Kisunla |
| Abbvie INC. | $656.61 | 2021-2023 | Ubrelvy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $625.50 | 2020-2025 | Jardiance |
| Avanir Pharmaceuticals, INC. | $614.98 | 2019-2021 | |
| E.R. Squibb & Sons, L.L.C. | $510.35 | 2019-2025 | Camzyos, Eliquis |
| Amarin Pharma, INC. | $400.18 | 2019 | |
| Biohaven Pharmaceutical Holding Company LTD. | $345.36 | 2022 | |
| Pfizer INC. | $330.80 | 2019-2025 | |
| Phathom Pharmaceuticals, INC. | $298.59 | 2024-2025 | Voquezna |
Show all 38 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniel Steiner listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.